Clinical trial

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

NCT01093794

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Co-administration of 50 mg sitagliptin and 500 mg metformin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention sitagliptin/metformin 50 mg/500 mg tablet Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Co-administration of 50 mg sitagliptin and 850 mg metformin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention sitagliptin/metformin 50 mg/850 mg tablet Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-04-01

PhasePHASE1

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

Co-administration of 50 mg sitagliptin and 500 mg metforminDRUG

sitagliptin/metformin 50 mg/500 mg tabletDRUG

Co-administration of 50 mg sitagliptin and 850 mg metforminDRUG

sitagliptin/metformin 50 mg/850 mg tabletDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01093794 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.